Fresh Leukopaks
Fresh Leukopaks
Leukopaks are collected from healthy IRB consented donors, tested negative for HBV, HCV, and HIV, using the Spectra Optia® Apheresis System, where cell-rich mononuclear cells are extracted using a continuous flow system directly into a sterile collection bag containing the anticoagulant ACD-A. Up to 12 Leukopak collections can be performed on the same donor in a given year, providing an ample amount of PBMCs for large-scale experiments and research studies. Additionally, 200-300mL of plasma can be collected at the time of the donor draw.
- Average 15 B TNC for full Leukopak
- Lower than 15% granulocytes
- 7 panel and CD34+ flow
- Recallable donors
- Bulk isolations available
- Up to 40ml of whole blood per Leukopak
- Same-Day Shipment from selected locations
- Special couriers for worry-free shipping
- Fresh and Cryopreserved Leukopaks available from the same collection
The CGT Global Difference
CGT Global is a Biospecimen Provider for a wide range of clinical and preclinical research projects. Our state-of-the-art laboratories and collection centers are located nationwide and provide end-to-end services: These services include:
- Process, isolate, and cryopreserve cells immediately after donor collection
- Amazing customer service and fast shipping
- Customize products to distinct study specifications
- Retain specific donor demographics and a safe, highly recallable donor pool
- HLA Typed Primary Cells
- Biobanked cells
Description
The following are mean percentages of cell populations in a Leukopak:
• T cells – 55%
• Monocytes – 27%
• B cells – 9%
• NK cells – 8%
• CD34+ stem cells – 0.1%
• Granulocytes – 2.4%
We do not guarantee the percentage of cell populations in a Leukopak, as they can vary from donor to donor.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
Custom Orders
We work closely with our customers to provide them with the product they need. For a custom order, please call and speak to one of our sales specialists at 530-303-3828.
Additional information
| Anticoagulant | |
|---|---|
| Format | |
| Grade | |
| Species | |
| Cell and Tissue Source | |
| Disease State | |
| Donor Attributes |
Product One-Sheet
Product Information Sheet
Certificate of Analysis
Material Safety Data Sheet
Publications
- Abelin et al. (2019) Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity 51(4): 766-779. Abstract
Request More Information
Figure 1. 7-Panel Analysis
